Olema Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018
Net Income	-99.34	-96.66	-104.79	-71.1	-23.99	-4.32	Upgrade
Depreciation & Amortization	1.62	1.67	1.66	1.39	0.01	0.01	Upgrade
Share-Based Compensation	17.54	17.26	18.83	15.91	3.11	0	Upgrade
Other Operating Activities	-6.65	-6	2.24	3.11	-0.86	1.23	Upgrade
Operating Cash Flow	-86.83	-83.73	-82.07	-50.69	-19.87	-3.08	Upgrade
Capital Expenditures	-0.14	0.01	-0.36	-1.58	-0.06	0	Upgrade
Change in Investments	-62.24	-4.87	91.84	-273.86	0	0	Upgrade
Investing Cash Flow	-62.38	-4.85	91.48	-275.44	-0.06	0	Upgrade
Share Issuance / Repurchase	142.02	133.42	0.48	1.39	221.19	0	Upgrade
Debt Issued / Paid	0	0	0	0	3.09	0	Upgrade
Other Financing Activities	-	-	-	-	134.12	-	Upgrade
Financing Cash Flow	142.02	133.42	0.48	1.39	358.4	0	Upgrade
Net Cash Flow	-7.2	44.84	9.89	-324.74	338.48	-3.08	Upgrade
Free Cash Flow	-86.97	-83.71	-82.43	-52.27	-19.92	-3.08	Upgrade
Free Cash Flow Per Share	-1.56	-1.85	-2.06	-1.32	-2.84	-1.19	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).